|
US6090382A
(en)
*
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
WO1997029131A1
(en)
*
|
1996-02-09 |
1997-08-14 |
Basf Aktiengesellschaft |
HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
|
|
US20090280065A1
(en)
*
|
2006-04-10 |
2009-11-12 |
Willian Mary K |
Uses and Compositions for Treatment of Psoriasis
|
|
KR20130001318A
(ko)
*
|
2002-07-19 |
2013-01-03 |
애보트 바이오테크놀로지 리미티드 |
ＴＮＦα 관련 질환의 치료
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
WO2006041970A2
(en)
*
|
2004-10-08 |
2006-04-20 |
Abbott Biotechnology Ltd. |
Treatment of respiratory syncytial virus (rsv) infection
|
|
CN102961746B
(zh)
|
2005-05-16 |
2016-06-15 |
艾伯维生物技术有限公司 |
TNFα抑制剂治疗腐蚀性多关节炎的用途
|
|
TWI424161B
(zh)
*
|
2005-11-01 |
2014-01-21 |
Abbvie Biotechnology Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
|
NZ611859A
(en)
|
2006-04-05 |
2014-12-24 |
Abbvie Biotechnology Ltd |
Antibody purification
|
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
|
EP2007426A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
|
|
EP2012586A4
(en)
|
2006-04-10 |
2010-08-18 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
|
|
US9605064B2
(en)
*
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
EP2010214A4
(en)
*
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
US20080311043A1
(en)
*
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
TWI527603B
(zh)
|
2006-06-30 |
2016-04-01 |
艾伯維生物技術有限責任公司 |
自動注射裝置
|
|
CA2667655A1
(en)
|
2006-10-27 |
2008-05-15 |
Abbott Biotechnology Ltd. |
Crystalline anti-htnfalpha antibodies
|
|
FR2909643B1
(fr)
*
|
2006-12-11 |
2011-03-04 |
Valois Sas |
Dispositif de distribution de produit fluide
|
|
US8092998B2
(en)
*
|
2007-05-31 |
2012-01-10 |
Abbott Laboratories |
Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
JP2010535771A
(ja)
|
2007-08-08 |
2010-11-25 |
アボット・ラボラトリーズ |
抗体を結晶化させるための組成物及び方法
|
|
NZ585702A
(en)
|
2007-11-30 |
2013-08-30 |
Abbott Lab |
Protein formulations and methods of making same
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
WO2009079078A1
(en)
|
2007-12-14 |
2009-06-25 |
Labogroup S.A.S. |
Delivering aerosolizable food products
|
|
MX2010007393A
(es)
*
|
2008-01-03 |
2010-11-09 |
Abbott Biotech Ltd |
Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.
|
|
AU2009204863B2
(en)
|
2008-01-15 |
2015-07-16 |
AbbVie Deutschland GmbH & Co. KG |
Powdered protein compositions and methods of making same
|
|
ES2403054T3
(es)
*
|
2008-05-23 |
2013-05-13 |
The Lauridsen Group, Inc. |
Métodos y composiciones para reducir la inflamación pulmonar en un animal
|
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
|
CA2760237C
(en)
|
2009-04-29 |
2017-11-14 |
Abbott Biotechnology Ltd. |
Automatic injection device and plunger for same
|
|
US20100278822A1
(en)
*
|
2009-05-04 |
2010-11-04 |
Abbott Biotechnology, Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
TWI584838B
(zh)
|
2009-12-15 |
2017-06-01 |
艾伯維生物技術有限責任公司 |
用於自動注射裝置之改良發射按鈕
|
|
US7985733B1
(en)
|
2010-01-06 |
2011-07-26 |
The Medicines Company |
Buffer-based method for preparing bivalirudin drug product
|
|
GB201005064D0
(en)
*
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
PL2563813T3
(pl)
|
2010-04-30 |
2016-01-29 |
Alexion Pharma Inc |
Przeciwciała anty-C5a i sposoby stosowania przeciwciał
|
|
CN105056232A
(zh)
|
2010-06-03 |
2015-11-18 |
阿布维生物技术有限公司 |
用于治疗化脓性汗腺炎(hs)的用途和组合物
|
|
CN103249432A
(zh)
|
2010-06-22 |
2013-08-14 |
科罗拉多大学董事会,法人团体 |
补体成分3的C3d片段的抗体
|
|
MX344727B
(es)
|
2010-11-11 |
2017-01-05 |
Abbvie Biotechnology Ltd |
Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
|
|
SG10201600576QA
(en)
|
2011-01-24 |
2016-02-26 |
Abbvie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
WO2014018668A2
(en)
*
|
2012-07-24 |
2014-01-30 |
Genoa Pharmaceuticals, Inc. |
Aerosol pirfenidone and pyridone analog compounds and uses thereof
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
US10058530B2
(en)
|
2012-10-25 |
2018-08-28 |
The General Hospital Corporation |
Combination therapies for the treatment of Alzheimer's disease and related disorders
|
|
EP2911664B1
(en)
|
2012-10-25 |
2019-05-08 |
The General Hospital Corporation |
Combination therapies for the treatment of alzheimer's disease and related disorders
|
|
US9757395B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
|
US9757529B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
|
JP6505079B2
(ja)
|
2013-03-29 |
2019-04-24 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
|
|
CA2910766C
(en)
|
2013-04-30 |
2020-12-15 |
Otitopic Inc. |
Dry powder formulations and methods of use
|
|
MX381503B
(es)
*
|
2013-05-23 |
2025-03-12 |
Aztherapies Inc |
Métodos para la liberación de cromolina.
|
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
AU2014340182B2
(en)
|
2013-10-22 |
2019-05-23 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
MY186840A
(en)
*
|
2014-08-26 |
2021-08-25 |
Amgen K A Inc |
Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
|
|
AU2017269839A1
(en)
|
2016-05-27 |
2018-11-22 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
KR20190044647A
(ko)
|
2016-08-31 |
2019-04-30 |
더 제너럴 하스피탈 코포레이션 |
신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
|
|
KR20200027971A
(ko)
|
2017-07-14 |
2020-03-13 |
싸이톰스 테라퓨틱스, 인크. |
항-cd166 항체 및 이의 용도
|
|
EP3654946A4
(en)
|
2017-07-20 |
2021-04-21 |
AZTherapies, Inc. |
CROMOLYNE SODIUM AND IBUPROFEN POWDER FORMULATIONS
|
|
WO2019023564A1
(en)
|
2017-07-27 |
2019-01-31 |
Alexion Pharmaceutical, Inc. |
ANTI-C5 ANTIBODY FORMULATIONS WITH HIGH CONCENTRATION
|
|
WO2019059953A2
(en)
|
2017-09-22 |
2019-03-28 |
Otitopic Inc. |
DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
|
|
US10786456B2
(en)
|
2017-09-22 |
2020-09-29 |
Otitopic Inc. |
Inhaled aspirin and magnesium to treat inflammation
|
|
MX2020004284A
(es)
|
2017-10-26 |
2020-10-28 |
Alexion Pharma Inc |
Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua).
|
|
KR20210076881A
(ko)
*
|
2018-03-08 |
2021-06-24 |
어플라이드 몰레큘라 트랜스포트 인크. |
경구 전달용 독소-유래 전달 구조체
|
|
US10765630B2
(en)
|
2018-03-16 |
2020-09-08 |
SEN-JAM Pharmaceutical LLC |
Methods and compositions to treat enteropathic arthritis
|
|
EP3802593B1
(en)
|
2018-05-31 |
2024-09-11 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
WO2019236345A1
(en)
|
2018-06-04 |
2019-12-12 |
Alexion Pharmaceuticals, Inc. |
DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) IN PEDIATRIC PATIENTS
|
|
US12312394B2
(en)
|
2018-06-28 |
2025-05-27 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-C5 antibodies
|
|
CA3105392A1
(en)
|
2018-07-02 |
2020-01-09 |
The General Hospital Corporation |
Powdered formulations of cromolyn sodium and .alpha.-lactose
|
|
EP4306128A3
(en)
|
2018-10-30 |
2024-03-27 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
|
|
CA3122989A1
(en)
|
2018-12-10 |
2020-06-18 |
The General Hospital Corporation |
Cromolyn esters and uses thereof
|
|
MX2021006968A
(es)
|
2018-12-12 |
2021-10-13 |
Kite Pharma Inc |
Antígeno quimérico y receptores de las células t, y métodos de uso.
|
|
JP2023520580A
(ja)
|
2020-04-06 |
2023-05-17 |
ザ ジェネラル ホスピタル コーポレイション |
コロナウイルス誘発炎症状態の処置方法
|
|
MX2022013176A
(es)
|
2020-04-24 |
2022-11-30 |
Millennium Pharm Inc |
Anticuerpos anti cumulo de diferenciacion 19 (cd19) y sus usos.
|
|
US20230277524A1
(en)
|
2020-05-22 |
2023-09-07 |
Trailhead Biosystems Inc. |
Combination therapy for treatment of viral infections
|
|
WO2022215054A1
(en)
|
2021-04-09 |
2022-10-13 |
Takeda Pharmaceutical Company Limited |
Antibodies targeting complement factor d and uses therof
|
|
EP4330284A2
(en)
|
2021-04-26 |
2024-03-06 |
Millennium Pharmaceuticals, Inc. |
Anti-clec12a antibodies and uses thereof
|
|
AU2022266583A1
(en)
|
2021-04-26 |
2023-10-19 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
|
CN116763763B
(zh)
*
|
2022-12-05 |
2024-08-30 |
齐鲁制药有限公司 |
一种司美格鲁肽吸入喷雾剂及其制备方法
|